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OBJECTIVE: E ndoscopic th ird  ven tricu lo stom y  (ETV) is curren tly  the  principal a lte r­
native to  ce reb ro sp in a l fluid shun t p la ce m en t in the  m an ag em en t of p ed ia tric  hy d ro ­
cep h alu s. C ost-effectiveness analysis can  help  d e term in e  th e  op tim al strategy for 
integrating  these  different ap p ro ach es .
M ETHODS: All patien ts (n =  28) w ho  u n d erw en t ETV at British C o lu m b ia 's  C h ild ren 's  
H ospital betw een  1989  and  1998  w ere  m atched  for age, pa thogenesis , and  num ber of 
p rev ious shun t p rocedu res, w ith patien ts trea ted  w ith ce reb ro sp in a l fluid shunts. To 
perform  a cost-effectiveness analysis, hyd ro cep h alu s-re la ted  resou rce  co nsum ption  
and  o u tc o m e  (determ ined  as th e  num ber of hyd ro cep h alu s trea tm en t-free  days during 
follow -up) w ere  then  retrospectively  identified. Cost data w ere  linked to  resou rce  use 
to  p rov ide a total cost for all resources used. Costs and ou tco m es w ere  d iscoun ted  
an n u a lly  at 5%  by standard  ec o n o m ic  analysis m ethods.
RESULTS: Twenty-four of 28 ETV patients had obstructive hydrocephalus. O ver equiva­
lent follow -up periods (m edian, 35 mo), the ETV success rate (defined by need for 
reoperation) was 54% . O n e  hydrocephalus-related death and one hem iparesis occurred  in 
the ETV group. No perm anen t procedure-related  m orbidity or m ortality w as seen in the 
shunt group. The cost/effect ratios for the tw o groups w ere similar. The additional incre­
m ental resource use by the shunt group included six readm issions and eight reoperations. 
ETV m ean costs per patient w ere $10 ,570  ±  $7628, versus $10,922 ±  $8722 for the shunt 
group (Canadian dollars for the year 2000). Costs accrued  m ore quickly for the shunt group 
as tim e passed. The additional increm ental ou tcom e benefit to the endoscopy group was 
86 treatm ent-free days (3.07 d per patient [95%  confidence interval, - 7 .5 6  to  13 .70 d]). 
Neither of these differences was statistically significant.
C O N C LU SIO N : In this m atched  cohort, ETV w as not significantly  less costly  or m ore 
effective over a m edian  35 m onths of fo llow -up, w ith a 54%  initial ETV success rate, 
even  before th e  add itiona l m orbid ity  and  m ortality  en c o u n te re d  w ere  taken  into 
acco u n t. The tim e co u rse  for the  acc ru ed  costs suggests tha t a larger cohort, longer 
fo llow -up , or h igher success rates a re  n eed ed  to  dem o n stra te  the  cost-effectiveness of 
this therapy .
KEY WORDS: Cost-effectiveness analysis, Cerebrospinal fluid shunt, Endoscopic third ventriculostomy, 
Hydrocephalus, Medical economics
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J™ n d o sco p ic  third ventriculostom y (ETV) is the principal 
alternative to cerebrospinal fluid (CSF) shunt placem ent 
in the treatm ent of hydrocephalus (4 ,8 ,15 ,16 , 21, 26, 27). 
The procedure has been advocated to avoid shunt placem ent 
in obstructive hydrocephalus for some time, bu t m ore re­
cently, advocates have argued for the inclusion of patients 
with com m unicating hydrocephalus of various causes (6, 9). 
Precise indications for this procedure rem ain som ew hat elu­
sive, and considerable variability exists in self-reported prac­
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tice patterns (17). W hen the procedure is successful, the sub­
sequent risks of CSF shunt infection and m alfunction are 
avoided. Even in experienced hands, however, the surgical 
risks of ETV are greater than those of routine shunt placement. 
Even with careful patient selection, this therapy will fail in a 
certain percentage of patients undergoing ETV, and these 
patients will still require shunt placem ent. A trade-off thus 
exists betw een an increased initial risk of com plications and 
possible need for subsequent shun t placem ent and the long-
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term  benefits of shunt independence. These trade-offs are also 
apparen t in considering the resources necessary to provide 
care along these tw o pathways. Patients undergoing ETV 
could potentially consum e m ore resources initially because of 
costs of the neuroendoscope, additional days of hospitaliza­
tion for evaluation, and possible shunt placem ent after ETV 
failure. This w ould be balanced against the long-term savings 
associated w ith avoiding subsequent shunt-related adm is­
sions. To address this question, we perform ed a cost- 
effectiveness analysis of a m atched cohort of children under­
going either ETV or CSF shun t p lacem ent for the treatm ent of 
hydrocephalus in an attem pt to determ ine w hether ETV is 
indeed a cost-effective alternative to shunt placement.
Cost-effectiveness analysis seeks to com pare the ratio of the 
costs of a treatm ent w ith the outcom e for a common m easure 
of effect between two different therapies. First, resource use 
for the different therapy arm s m ust be determ ined from  a 
specific perspective (e.g., patient, third-party  payer, society as 
a whole), and a m onetary cost m ust be determ ined for each of 
the resources used. Second, a com mon m easure of effective­
ness m ust be found and m easured for each of the therapy 
arms. W hen costs and outcom e events occur a t different points 
over tim e, an adjustm ent tha t recognizes a preference for 
im m ediate benefits and deferred costs is usually m ade by 
applying a d iscount to future costs and benefits. Finally, the 
tw o therapy groups are com pared by use of the ratios of cost 
to outcomes. A therapy may be dom inant that is both less 
costly and associated w ith a better outcom e, or an incremental 
additional cost may be associated with an im proved outcome 
for one or another of the therapies (12).
PATIENTS AND METHODS
We conducted a case-control analysis of the treatm ent of all 
patients undergoing ETV a t British Colum bia's Children's 
Hospital, Vancouver, BC, Canada, between 1989 and 1998. To 
com pare their costs and outcom es w ith those seen in the shunt 
treatm ent of hydrocephalus, we m atched the ETV patients 
w ith a control group of children treated w ith shunts. To con­
trol for other possible influences on outcom e other than the 
procedure of interest, the groups were matched by the patho­
genesis of hydrocephalus and the patien t's  age a t the tim e of 
the qualifying ETV or shun t placem ent (elsewhere referred to 
as the index procedure). In addition, as a m arker for the 
complexity of the hydrocephalus in those patients undergoing 
ETV instead of a shunt revision, we m atched patients for the 
num ber of total hydrocephalus-related procedures (excluding 
reservoirs or external ventricular drains) perform ed before the 
index procedure. The m atching process was accom plished by 
use of a com puterized practice database and was completed 
before any review of charts to determ ine either the costs or 
outcomes.
We examined hospital adm issions, em ergency room  visits, 
and office visits. For each of these encounters, we tabulated 
the num ber of im aging studies perform ed, including plain 
x-ray, com puted tom ographic (CT) scanning, m agnetic reso­
nance imaging, and ultrasound studies. For hospital adm is­
sions, we recorded the length and location of the patien t's  stay 
and the use and duration of intravenously adm inistered anti­
biotics. We evaluated operative events for their duration and 
the type of CSF shunt hardw are or ventriculoscope used. We 
included only resource consum ption tha t was related to hy­
drocephalus. For exam ple, if a patient w ith a brain tum or was 
adm itted for chem otherapy, this encounter was not included. 
However, if the same patient visited the em ergency room for 
vom iting and a head CT scan was obtained to check ventric­
ular size, this em ergency room encounter was included, al­
though the subsequent adm ission for dehydration after a neg­
ative shun t evaluation was not. Case and control patients were 
followed up for equivalent periods by limiting consideration 
to the po in t of shorter follow-up between the pair, so tha t each 
patient had equal exposure in the combined cohort. In deter­
m ining resource use, the retrospective nature of the study 
limited our perspective to tha t of a third-party  payer. We 
focused on hospital and physician resource use and could not 
consider items such as out-of-pocket family expenses or 
changes in parental productivity.
Cost-effectiveness analysis requires tha t the outcom es of the 
therapies have a com mon unit of m easure. We m easured the 
effects of therapy in term s of days free of the hydrocephalus 
treatm ent. This was calculated as the total days of follow-up, 
less tim e spent hospitalized for hydrocephalus-related treat­
m ent, and less a 14-day addition for each hospital adm ission 
to account for the im pact of the prehospitalization illness and 
postdischarge recovery time. Com plications of therapy that 
would not otherw ise be apparen t in a sim ple accounting of the 
duration of illness were recorded separately.
U nit costs for resources were draw n from  several sources, 
including data provided by the British Colum bia's C hildren's 
Hospital Health Services Study U nit, as well as the University 
of M ichigan Health Care System 's Clinical Information and 
Decision S upport Service, by use of the TSI Costing System 
(Transition Systems, Inc., Boston, MA) (24). Professional fees 
were taken from both the Canadian published fee schedule for 
the Medical Services Commission: British Columbia (20) and 
sim ilar private fee schedules from  the United States tha t were 
m odified to account for likely reim bursem ent am ounts, given 
our choice of third-party  payer perspective. A range of cost 
estim ates was developed by contributions from both Cana­
dian and United States data sources. This cost range was used 
to assess the sensitivity of the study conclusions to the specif­
ics of the cost data. For the Canadian data set, costs for head 
CT scans and m agnetic resonance im aging studies were cal­
culated as a capital cost (initial outlay and m aintenance/ 
[service life X stud ies/y r]) +  labor and nonlabor costs. In 
addition , we assum ed that about one-third of these studies 
would require some form of sedation. We calculated the costs 
of neuroendoscope use on a sim ilar basis. O perative time, 
em ergency room  costs, hospital day costs, and intensive care 
un it costs were based on yearly expenses, both direct and 
indirect, divided by the num ber of patient-days per year, bu t 
do not include capital costs. For hardw are costs, we used the
70 | VOLUME 51 | NUMBER 1 | JUI.Y 2002 www.neurosurgery-online.toni
C ost- effectiveness of  En d o s c o p ic  T h ir d  V entriculo stom y
actual charges incurred by the hospital for the items. For the 
United States data, the TSI cost system com bines both fixed 
and variable direct cost (based on assigned relative value 
units) as well as apportioned indirect costs for overhead de­
partm ents. For clarity, all dollar am ounts are reported in Ca­
nadian dollars for the year 2000. We discounted both costs and 
effects at a rate of 5% annually as they accrued to account for 
the tim e preference for im m ediate benefits and delayed costs 
as opposed to  im m ediate costs and delayed benefits.
Data w ere sum m arized w ith descriptive measures. Mean 
data w ere com pared by S tudent's t test. A cost model was 
developed that used the cohort's resource use pattern  over 
tim e to evaluate the effect of changes in the success rate of ETV 
on the cost stream over time. Tabulation and statistical com­
parisons were perform ed w ith M icrosoft Excel (Microsoft 
Corp., Redm ond, WA) and SPSS software (SPSS, Inc., Chicago, 
IL).
RESULTS
Between 1989 and 1998, 28 patients underw ent 29 ETV 
procedures, w ith all b u t 5 of these undergoing the procedure 
in the last 3 years of this period. By use of the practice 
database, 28 patients treated for hydrocephalus with CSF 
shunts could be identified to match the 28 patients undergoing 
ETV placem ent. As intended, the tw o groups are com parable 
for the m atched factors of pathogenesis of hydrocephalus, age, 
and num ber of previous shun t procedures perform ed. The 
choice of endoscopic versus shunt treatm ent in individual 
cases seemed to be determ ined by the prevailing practice 
pattern  of the tim e, w ith m ost of the shun t patients in the 
cohort being treated in the 1980s, before renewed interest in 
third ventriculostom y. Table 1 details the features of the case 
and control patients. Twenty-one of 28 patients in each group 
were undergoing their first procedure for hydrocephalus, ex­
cluding such tem porary m easures as external drainage. The 
rem ainder had undergone from 3 to 10 procedures before the 
index third ventriculostom y or shun t procedure. Twenty-four 
of 28 patients in the ETV group had obstructive hydrocepha­
lus as a result of either aqueductal stenosis or lesions obstruct­
ing the aqueduct or fourth ventricle. The m edian follow-up 
period w as 34.7 m onths (range, 87 d to 6 yr). Five patients in 
the ETV group died, four of causes unrelated to  their hydro­
cephalus treatm ent. Excluding these patients, all b u t one had 
m ore than 2 years of follow-up. One patien t in the shun t group 
died from causes unrelated to hydrocephalus during  the 
follow-up period.
Am ong ETV patients, the procedural success rate, as de­
fined by the avoidance of either repeat third ventriculostom y 
or shun t placem ent, was 54%. One patien t in whom the p ro ­
cedure initially failed underw ent a successful repeat ETV 3 
weeks after the initial procedure and thereafter remained 
shunt-free. Two patients w ith m eningomyelocele and tw o 
w ith meningitis as the cause of hydrocephalus underw en t the 
procedure. Of these, only one of the m eningomyelocele p a ­
tients w as able to remain shunt-free. Ten of 13 ETV failures
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occurred w ithin 6 m onths. The latest failure, occurring a t 25 
m onths after the initial procedure, was associated w ith the 
patien t's death and is discussed m ore fully below. Figure 1, a 
Kaplan-M eier survival plot, dem onstrates the hazard of first- 
procedure failure for both the ETV and shun t groups, consid­
ering all available follow-up inform ation, w ithout lim iting 
consideration to  the po in t of shorter follow-up betw een the 
matched pairs.
Resource use during  the hospitalization for the index p ro ­
cedure w as higher in the ETV group (Table 2). The ETV group 
had longer length of stay (4.8 ± 6.0 versus 3.8 ± 2.4 d [mean 
± SD]), required more operative tim e (2:20 h ± 48 min versus 
1:35 h ± 22 min), and underw ent more reoperations (4 versus 
1) than the shun t group. A reusable neuroendoscope was 
typically used, and alm ost all patients w ere m anaged on the 
w ard after surgery, m ost w ithout a ventriculostom y catheter 
or intracranial pressure monitor.
During the subsequent m atched follow-up periods, the re­
source use of the shunt group slightly exceeded tha t of the 
ETV group. During the m edian follow-up of 34 m onths, the 28 
shunt group patients required m ore readm issions (22 versus 
16), w ith a longer length of stay (4.1 ± 3.9 versus 3.38 ± 2.3 d), 
including greater use of the intensive care un it (7 versus 1 d). 
The increased length of stay in the shun t cohort could be fully 
explained by hospitalizations required to treat tw o shun t in­
fections tha t occurred in this group and did not appear to 
represent a confounding change in practice patterns. Table 2 
further details aspects of the cohorts' resource consum ption.
Treatm ent com plications occurred in tw o patients in the 
ETV group. The first of these was a persistent, if m ild, hem i­
paresis tha t occurred in a Pair 10 patien t after the perform ance 
of an otherw ise successful ETV. A postoperative head CT scan 
did not show a hem orrhage. The second com plication oc­
curred in a Pair 7 patient, a 12-year-old child w ith aqueductal 
stenosis w ho initially presented w ith headaches, nausea, and 
vom iting and a new sixth nerve palsy. Three m onths after the 
patient underw ent an apparently  successful ETV, a head CT 
scan dem onstrated unequivocal reduction in the size of his 
ventricles. H e becam e asym ptom atic after ETV and remained 
so for 18 m onths b u t was then lost to our follow-up. He 
presented elsewhere at 25 m onths after ETV, was obtunded, 
and subsequently died. At autopsy, he was noted to have 
massive hydrocephalus, and the third ventricular fenestration 
w as found to  be closed.
Analysis of the cost data allowed us to generate low and 
high estimates for the dollar cost for particular resource uses 
(Table 3). These values do not always represent a Canadian 
versus United States cost experience, b u t rather a mix of the 
high- and low-end estim ates we identified. For m any items, 
such as hospital day costs, a range of potential figures was 
available tha t depended, in the TSI system , on patien t acuity. 
Given tha t acuity data w ere not available for patients in our 
cohort, we chose an acuity representing the lower 33% of the 
cost range.
Com bining the resource consum ption w ith the assigned 
costs, we calculated the total and average costs for the cohort
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TABLE 1. Cohort of matched endoscopic third ventriculostomy and shunt patients 
Endoscopic third ventriculostomy Cerebrospinal fluid shunt placem ent
Pair no.
Pathogenesis
No. of prior 
procedures Age* (yr) Pathogenesis
No. of prior 
procedures Age* (yr)
1 Aqueductal stenosis 0 0.19 Aqueductal stenosis 0 0.02
2 Aqueductal stenosis 0 0.28 Aqueductal stenosis 0 0.01
3 Aqueductal stenosis 0 0.29 Aqueductal stenosis 0 0.04
4 Aqueductal stenosis 0 0.50 Aqueductal stenosis 0 0.61
5 Aqueductal stenosis 0 0.78 Aqueductal stenosis 0 0.3 5
6 Aqueductal stenosis 0 1.45 Aqueductal stenosis 0 1.16
7 Aqueductal stenosis 0 4.03 Aqueductal stenosis 0 10.32
8 Aqueductal stenosis 0 4.58 Aqueductal stenosis 0 8.1 5
9 Aqueductal stenosis 3 1.35 Aqueductal stenosis 2 6.72
10 Aqueductal stenosis 8 12.13 Aqueductal stenosis 4 7.73
11 Meningitis 0 0.36 Meningitis 0 0.57
12 Meningitis 0 0.50 Meningitis 0 0.05
13 Meningomyelocele 2 16.23 Meningomyelocele 2 8.44
14 Meningomyelocele 3 6.04 Meningomyelocele 3 5.68
15 Tecta I cavernous malformation 4 15.89 Tumor: cerebellar 4 16.34
16 Tumor: brainstem 0 15.02 Tumor 0 6.13
17 Tumor: cerebellar 0 2.16 Tumor: cerebellar 0 4.38
18 Tumor: hypothalamic 0 0.40 Tumor: thalamic 0 0.42
19 Tumor: midbrain 0 6.92 Tumor: midbrain 0 3.14
20 Tumor: midbrain 0 9.58 Tumor: midbrain 0 14.81
21 Tumor: pineal 0 0.93 Tumor: pineal 0 0.01
22 Tumor: pineal 0 10.40 Tumor: pineal 0 10.37
23 Tumor: pineal 0 15.13 Tumor: pineal 0 12.88
24 Tumor: pineal 0 17.20 Tumor: pineal 0 11.90
25 Tumor: tecta I 0 5.57 Tumor: tecta I 0 4.31
26 Tumor: tecta I 0 11.54 Tumor: midbrain 0 11.21
27 Tumor: tecta I 5 14.87 Tumor: cerebellar 6 12.97
28 Tumor: tecta I 9 0.61 Meningomyelocele 7 0.72
' Age in years at time the index procedure was performed.
for the matched follow-up periods (m edian, 35 mo). As p re­
viously noted, costs tha t occurred after the initial hospitaliza­
tion w ere discounted at a rate of 5% per year. The cost for the
initial adm ission (considered from the po in t of the index sur­
gical procedure onw ard) was typically higher in the ETV 
group ($6603 ±  $4577 to  $10,999 ±  $7216) than in the shunt
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FIGURE 1. Graph o f survival curve for index procedure. Time to first 
failure for E TV  and shu n t groups. Note that the curves cross at about 34- 
months.
group ($5128 ±  $2807 to $9023 ±  $4849). Subsequent adm is­
sion costs w ere sim ilar in both groups, w ith  a low estim ate of 
$5031 ±  $3195 and a high estim ate of $8430 ±  $4646. O utpa­
tient care accounted for approxim ately 10% of the total cohort 
costs in both  groups.
Including all resources used, patients in the ETV group had 
low er mean costs ($10,570 ±  $7628 to $17,464 ±  $12,533) than 
those in the shunt group ($10,922 ±  $8722 to $18,459 ± 
$14,017), b u t these differences w ere not statistically significant. 
Figure 2, using the high-cost estimates, dem onstrates the time 
course over w hich these costs accrued. As expected, the initial 
expenditure for the ETV group is greater than tha t for the 
shunt group, b u t after 36 months, the cost stream s cross and 
diverge because of the increased delayed expenses for the 
shunt group relative to the ETV group.
The ETV group enjoyed an additional 86 days free of treat­
m ent of hydrocephalus over the shunt group during  the 
matched follow-up period, again not a statistically significant 
difference. The cost-effectiveness ratios for the tw o therapies 
w ere between $11.00 and $18.00 dollars per patient per day 
free of treatm ent of hydrocephalus for the ETV group and 
between $11.40 and $18.17 per patient per day for the shunt 
group. On an increm ental basis, ETV w as nom inally dom i­
nant, tha t is, both  slightly less expensive and more effective
TABLE 2. Resource usea
Endoscopic third 
ventriculostomy
Shunt f  
value
Initial hospitalization
Length o f stay 4.82 ± 6.06 d 3.79 ± 2.4 d NS






Length o f stay
Cohort total 54 d 91 d
M ean± 5D 3.38 ± 2.28 d 4.14 “  3.93 d'- NS
Reoperations 18 2b
ICU days 1 d 7 d
Shunt infection 0 2
Nonhydrocephaius 4 1
death
Hydrocepha 1 us-relatec 1 0
death
'* NS, nol significant; SD, standard deviation; ICU, intensive tare unit.
''Shunt group mean length of slay ignoring two admissions for infection,
was 3.25+ 2.31 days.
than shunt therapy (cost/effect ratio <0), w ith  neither differ­
ence statistically significant (Tables 4 and 5).
Sensitivity Analysis
Varying the discount rate from 1 to 10% produced no sig­
nificant changes in the relationship betw een the ETV and 
shunt groups for either costs or effects. Similarly, altering 
specific costs by as m uch as 25% did not dram atically affect 
the relationship of the ratios (data not shown). Similarly, 
increasing or decreasing the posthospitalization recovery pe­
riod by 7 days did not significantly alter the results. As illus­
trated by Figure 3, the ETV costs could be grouped by the 
success or failure of the initial procedure, w ith  the unsuccess­
ful ETV cases following a cost curve sim ilar to that of the 
shunt patients, as expected. U sing average cost data for the 
successful and unsuccessful ETV groups, we explored the 
effects of different rates of ETV success on the cost streams. 
Figure 4 dem onstrates the results w ith  a hypothetical success 
rate of 75%, dem onstrating tha t the total cum ulative costs for 
this cohort w ould cross at about 12 m onths and continue to 
diverge thereafter.
Complications and Quality-of-Life Assessment
The main lim itation of cost-effectiveness analysis is tha t it 
cannot m easure different outcomes, yet tw o patients in the 
ETV group experienced complications, one of w hich w as fatal.
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Antibiotics $17 $39 Per dose
Neurosurgical consultation 
Em ergency room , ward $40 $105
Per visit
O ffice  visit $36 $90
Neurosurgical professional fees 
CSF sh u n t p lacem ent/revision $904 $1550
Per case
E ndoscopic third ventriculostom y $1153 $2250
CSF sh u n t tap $32 $250
Anesthesia professional fees $210 $450 Per case
Radiology professional fees $75 $150
Operative costs
O pera tive tim e $470 $900 Per hour
A n esthetic  agents/disposables $43 $150 Per case
N e u roendoscop ic  use $450 $600 Per case
Hardware costs
Shun t valve $526 $1500
Distal sh u n t tubing $80 $120
Ventricular catheter $60 $90




H ead C T scan $250 $350
Brain M R1 $385 $400
Shun t series/plain x-ray $55 $100
N uclear sh u n t infusion study $95 $175
Laboratory costs 
Basic b lo o d  count/chem istry $20 $40
Per study
CSF analysis (including culture) $50 $80
Hospital day costs
In tensive care unit $1720 $2500 Per day
W ard $575 $850 Per day
Em ergency room $110 $175 Per visit
3 Canadian dollar based upon the value at year 2000. CSF, cerebrospinal 
fluid; CT, computed tomographic; MR I, magnetic resonance imaging.
These outcomes are poorly represented in the above analysis. 
To investigate this further, we used quality-adjusted life-year 
(QALY) techniques to provide an alternative view of the data 
(12). For the matched pair that included the patient who died, 
we allowed the follow-up to continue to the last known con­
tact with the patient in the shunt group. We assigned a QALY 
weight to the days in the follow-up period as follows: 1, day 
















-■—  Number of Patient 
Pairs remaining in 
dataset
FIGURE 2. Graph shoioing cum ulative average costs fo r  cohort in Cana­
dian dollars for the year 2000. Error bars, standard error.
0.2, days hospitalized or in 14-day recovery period; and 0.0, 
death. These values are arbitrary b u t sim ilar to those in the 
literature (25). W hen the outcom e data in QALYs were recal­
culated, the ETV treatm ent rem ained less costly, b u t it now 
becam e less effective than the shun t group (QALYs, 73.9 ver­
sus 78.5), yielding an incremental benefit in the shun t group at 
a cost of $2153 to $6187 per additional QALY for the low and 
high estimates, respectively.
DISCUSSION
Is ETV a cost-effective alternative to  shun t placem ent in 
m anaging pediatric hydrocephalus? Given the presum ed ben­
efits of shunt independence for patients undergoing successful 
ETV and their reduced reliance on the healthcare system , this 
m ight seem to be obviously true. However, up  to now, data to 
support this conclusion have been limited. Barlow and Ching 
(2) retrospectively identified 23 patients from a group treated 
with CSF shunts whom im aging studies show ed to  be poten­
tial ETV candidates. They followed the patients' resource con­
sum ption over 2 years and calculated tha t if these patients had 
undergone ETV with an 80% success rate, 18 repeat operations 
and 148 hospital days could have been avoided. H owever, as 
they note, this analysis assum ed a 0% ETV complication rate 
and did not consider additional shunt m alfunctions am ong 
patients w ho needed shun t placem ent after failed ETV. Ibanez 
et al. (14) reported tha t an 82.7% procedural success rate 
allowed an estim ated savings of 9 adm issions, 8 reoperations, 
and 100 days of hospitalization over a 4-year period in a
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Time to first 
failure (mo)rf
ETV Shunt ETV Shunt
1 12.62 11.47 11.47 0.39 3.58
2 29.41 27.22 27.08 10.12 9.99
3 32.57 30.6 30.6 — —
4 43.67 40.31 40.15 — —
5 55.87 50.49 50.49 — —
6 34.92 32.03 32.52 2.99 —
7 25.27 23.96 21.77 25.3 7.76
8 40.26 37.3 37.26 — —
9 21.2 19.63 20.23 0.13 25.3
10 30.5 28.53 28.69 — —
11 30.33 26.93 28.55 0.13 —
12 12.06 10.91 11.37 0.62 —
13 21.46 19.92 20.41 — 34.05
14 30.13 28.13 27.1 0.33 0.16
15 45.71 42.08 40.99 — 1.28
16 2.86 2.33 1.64 — 0.26
17 35.06 32.77 32.9 0.03 —
18 37.46 34.92 34.95 — —
19 73.12 64.11 63.57 — 59.42
20 52.88 48 47.49 — 35.33
21 29.31 27.65 27.49 — —
22 12.13 10.87 11.56 1.02 —
23 28.66 26.53 27.06 0.82 —
24 44.27 40.76 40.07 — 2.17
25 42.49 39.26 37.23 — 17.58
26 41.24 38.28 36.6 — 2.79
27 38.19 34.29 34.49 6.05 8.41
28 64.64 54.93 57.01 0.69 7.79
' FTV, endoscopic ihird venlriculosloniy.
''Total number of follow-up months.
c Months free of treatment of hydrocephalus after 5% annual discount lo 
account for lime preference (see lexl).
Time lo first FTV or shunl failure as defined by need for reoperalion; —, 
shunl or FTV reoperalion did nol occur in follow-up period.
cohort of 58 patients. H ow ever, the com parison population 
from which the shun t experience was draw n was com posed 
predom inantly  of adu lt patients with chronic idiopathic adult- 
onset hydrocephalus. This probably is poorly reflective of the 
pediatric shunt experience.
W hat accounts for the lack of more robust gains seen with 
ETV in our data set? The patients represented in our ETV 
cohort are typical of those reported in other series. The pro­
cedural success rate is lower than the 75 to 80% reported by 
Cinalli e t al. (8, 9) and G oum nerova and Frim (13) b u t com­
parable to outcom e assessm ents by Brockmeyer et a I. (4) and 
Tuli e ta l. (27). Similarly, the patients in the shunt group do not 
seem to have had an unusual experience with regard to shunt
failure. The cost estimates for individual items produced total 
costs for shunt-related adm issions tha t are com parable to 
those in the literature (3, 11, 18, 22), and the total cost for 
m anaging the cohort was also sim ilar to  models reported by 
Cochrane et al. (10). The resource use experience by the cohort 
reflects the practice patterns of the senior authors in a tertiary 
care setting w ithin the Canadian H ealthcare system. Possibly, 
other providers with different practice patterns would p ro­
duce m arkedly different patterns of resource use, b u t given 
the overall similarity of resource consum ption betw een the 
ETV and shunt groups, it is unlikely tha t practice patterns 
account for the lack of a noticeable difference betw een the 
groups. M ore likely, the deaths of four patients in the ETV 
cohort relatively early in the follow-up period from diagnoses 
other than their hydrocephalus (mostly from brain tum ors) 
limited the potential economic and outcome benefits of the 
procedure. Finally, our m ean 35-month follow-up period 
clearly represents only a small w indow  of tim e in the life 
history of many of these children. If late failures after ETV are 
much rarer than those for children with CSF shunts, longer 
follow-up w ould presum ably im prove the cost-effectiveness 
ratios seen.
Two key factors m ost likely account for the majority of the 
variability in the cost stream s of ETV and shunt treatm ent: the 
ETV success rate and the rate of ETV complications. The ETV 
success rate, in turn , is linked principally to patien t selection. 
O ur analysis supports these conclusions. For those with 
pathogeneses typically associated with obstructive hydro­
cephalus, the success rate was 58%, versus 25% for patients 
with m eningomyelocele or meningitis. Variations in item costs 
and discount rate had no noticeable im pact on our outcome, 
whereas changes in the success rate had a more obvious effect, 
as seen in Figures 3 and 4. It has been argued tha t because the 
benefits of ETV are so dram atic com pared with shunt treat­
ment, then perhaps limiting its use to cases in which there is 
an anticipated success rate of 70% is too restrictive. In fact, 
Buxton et al. (7) argued that children less than 1 year old be 
considered candidates, despite a 23% success rate. A lthough 
perhaps a higher percentage of such young patients m ight in 
due course undergo subsequent successful repeat ETV, our 
analysis would suggest that, a t least over the first 3 years after 
the procedure, ETV remains more costly w ithout producing 
significant benefit over shunt treatm ent until the success rate 
is higher than 55%. In addition, broader indications for a 
procedure may be associated with higher procedural com pli­
cation rates. For patients whose life expectancy falls below the 
po in t at which the benefits can be seen to exceed the costs, 
serious consideration should be given to  the CSF shunt treat­
m ent as the prim ary m ode of therapy. O ur attem pt to incor­
porate the adverse outcom es in the ETV group shows the 
im pact of a single serious adverse event. A lthough m any of 
the large series cited above report adm irably low complication 
rates, a num ber of case reports attest to the potential for 
serious harm  (1, 5, 19, 23).
Late deterioration after apparently  successful ETV has been 
reported by others. Cinalli et al. (8) noted one such failure in
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TABLE 5. Cost-effectivenessi'
ETV CSF shunt P value
Average cohort costs
High estim ate
M ean±  SD $17,464 ± $12,533 $18,459 ± $14,017 0.78
M edian $12,534 $12,843
Low  estim ate
M ean±  SD $10,570 ± $7628 $10,922 ± $8722 0.87
M edian $7874 $7667
Cohort outcome (effectiveness)6
D iscoun ted  days free o f  hydrocephalus treatm ent 26,914 26,828 0.92
(total for entire cohort)
Cos t-effectiveness ra tio‘
Low -cost estim ate $11.00 $11.40
H igh-cost estim ate $18.17 $19.30
' FTV, endoscopic third ventriculostomy; CSF, cerebrospinal fluid; SD, standard deviation. Costs are in Canadian dollars for the year 2000. 
''Mean difference, 3.07+ 27.47 days.
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FIGURE 3. Graph showing average cumulative costs by success or failure  
of initial third ventriculostomy. E rror bars, standard error.
a patien t 6 years after perform ance of the procedure. O ur 
experience of a mortality caused by late failure highlights the 
need for continued vigilance, even after an apparently  suc­
cessful procedure with confirm atory im aging, in the m anage­
m ent of these patients.
CONCLUSIONS
In this cost-effectiveness analysis using a case-control de­
sign, we have dem onstrated tha t for this particular cohort, 
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FIGURE 4. Graph showing modeled total costs for 75% E TV  success 
rate.
cantly less costly or m ore effective a t producing days free of 
hydrocephalus than shun t treatm ent. As expected, the ETV 
group 's resource use was initially higher than tha t of the shunt 
group, b u t subsequent resource use by the shun t group ex­
ceeded tha t of the ETV group such tha t by 3 years after shunt 
placem ent, the cost curves diverged, w ith ETV clearly less 
costly. H ow ever, ETV in this series was associated w ith a 
higher rate of com plications, which, when considered in the 
analyses, tended to lim it the beneficial effects of the reduced 
frequency of hydrocephalus sym ptom s and reduced medical
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resource use. The tim e course for the accrued costs suggests 
tha t a larger cohort, longer follow-up, or higher success rates 
may be able to dem onstrate the cost-effectiveness of this ther­
apy more clearly.
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COMMENTS
" T h is  is a heroic attem pt to do the nearly im possible, namely 
I  perform  a cost-effectiveness analysis of th ird  ventriculos­
tom y com pared w ith shunting for children with hydrocepha­
lus. The authors evaluated 28 age- and etiology-matched pairs 
of patients. The major conclusions were tha t 1) the endoscopic 
third ventriculostom y (ETV) procedure ultim ately failed in 
46% of cases with a m edian of 35 m onths of follow-up, and 2) 
there was no statistically significant difference betw een the 
tw o procedures in term s of costs accrued over the period of 
the study.
There are some obvious drawbacks to the study, most of 
which are acknowledged by the authors themselves: the shunts 
were used earlier in the course of the study, and the ETVs were 
performed later. The patients with meningitis and meningomy­
elocele could have been anticipated to fare poorly with ETV and 
probably should have been excluded. The costs entailed are 
dubious. Still, the study was probably as well done as practically 
possible, and the conclusions are probably valid.
The two complications in the ETV group (one death and one 
hemiparesis) warrant comment. It has been stated by other au­
thors that one of the dangers of ETV is that physicians and 
parents often assume that the child is shunt-independent after 
the procedure; herniation and death may occur in the absence of 
the vigilance that always attends the shunt-dependent child. 
Shunts are not considered dangerous procedures, bu t ETV is 
associated with a num ber of other complications not seen in this 
study: aneurysm formation on the basilar artery, basilar perfora­
tion, panhypopituitarism, and memory loss. It is to be anticipated 
that any of these adverse occurrences would prom pt a malprac­
tice suit, which might well result in a judgm ent or settlement in 
the millions of dollars. This consequence dwarfs any of the 
analyses presented in this study. In theory, the malpractice com­
ponent of the relative value unit for each of the procedures takes 
this into account, but this is very arbitrary for a relatively new 
procedure such as ETV. One m ust ask how im portant any cost 
analysis is in the setting of a relatively uncommon condition on 
a global scale. In the final analysis, outcome is the prim e issue, 
and cost is appropriate to consider only if the outcomes are 
identical. Until the true indications for ETV are defined, this 
analysis m ust be considered preliminary, at best.
Leslie N. Sutton
Philadelphia, Pennsylvanin
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T his study is a cost-effectiveness analysis of ETV. It com­
pares the financial costs for 28 patients who underw ent 
ETV w ith those for m atched patients w ho received shunts. It 
also provides a brief quality-of-life-year analysis. The financial 
costs were sim ilar in the ETV and shunt patients. ETV had a 
higher upfront cost, bu t the shunt patients accrued costs more 
quickly as tim e passed. The study suffers from including only 
a small group of patients. This results in fairly w ide confi­
dence intervals in term s of the cost estimates. Single adverse 
events may have a substantial im pact on relative costs. The 
ETV experience is also relatively small, and it may include an 
im portant learning period that influences the length of sur­
gery, complications, and success rate. The authors indicate 
that a larger study w ith longer follow-up m ight clarify these 
issues. The challenge is for ETV advocates to dem onstrate its 
cost and quality-adjusted life-year effectiveness.
Jam es M. D rake
Toronto, Ontario, Canada
" T h e  care and thoughtfulness w ith which the authors de­
I  signed and carried out this study are impressive. Ulti­
mately, cost-benefit analysis is an expression of the long-term
efficacy of a surgical procedure (in this case, ETV). The au ­
thors have dem onstrated to my satisfaction that the cost- 
effectiveness of ETV is com parable to that of shunting after 
several years, even when their success rate for the initial ETV 
is slightly lower than those reported in some other series. 
After 36, m onths the trend is tow ard increased effectiveness 
of ETV vis-a-vis shunting. Given the life expectancy of the 
patient cohort, one m ight anticipate that there would ulti­
mately be an unequivocal advantage to ETV in properly se­
lected patients.
The issue of patient selection is also addressed. It is pointed 
out that, on the basis of the presen t data, a success rate of at 
least 55% is necessary to produce a significant benefit of ETV 
over shunting. In spite of the fact that the ETV success rate in 
infants is considerably lower than this, if one takes into ac­
count that the cost analysis m ust be am ortized over the life of 
such a patient, it still m ight be found that ETV is w orth trying. 
The authors have presented a careful and thought-provoking 
study.
Paul H. C hapm an
Boston, Massachusetts
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